Saturday, July 10, 2021

Ultragenyx earns 2 rare disease drug approvals—and a validated commercial strategy


Rare disease pharma companies spend a lot of time looking for patients and investing in keeping them on their meds.

But what happens during a pandemic lockdown? At Ultragenyx, patient support teams kicked into high gear, making thousands of proactive outbound calls to find out what patients needed to continue their treatment.

It had just nabbed a second approval for FGF23 hormone blocker Crysvita in June 2020 for tumor-induced osteomalacia. The first nod for the drug, developed by Ultragenyx and partner Kyowa Kirin, came in April 2018 for X-linked hypophosphatemia.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

And while Ultragenyx support teams worked with those patients, the biopharma’s management reached out to the FDA to seek approval for temporary home administration of the injection.

RELATED: Ultragenyx’s Crysvita scores FDA nod in 2nd ultra-rare bone disorder

As it turned out, the pandemic helped Ultragenyx solidify its rare disease commercial model. One important strategy it validated was its practice of maintaining equal-sized sales teams in the field and patient diagnostic teams in medical affairs because “patient diagnosis is critical,” Chief Commercial Officer Erik Harris said.

“The key to success for any rare disease business, and it has been the key for us, is the ability to identify and confirm diagnosis of rare disease patients,” Harris said. “What you find with rare disease (drug) launches is they often stall after the first year or so because of the inability to find patients.”

The consistent strategy has been important for Ultragenyx’s other 2020 approval, also in June, for Dojolvi, a metabolic supplement for a rare group of disorders; those patients cannot convert certain fatty acids into energy. Ultragenyx is now just rolling out Dojolvi but is using lessons learned from its commercialization of Crysvita.

RELATED: Ultragenyx scores 2nd FDA approval in as many weeks for ultra-rare metabolic disease drug Dojolvi

The focus is again on finding patients. For Dojolvi, that means locating and contacting the estimated 2,000 to 3,500 people affected, starting with the 160 metabolic centers where a concentration of patients are treated. Ultragenyx plans to eventually move that model outside those centers to reach more patients and physicians, Harris said, much as it’s done with Crysvita.

Ultragenyx did get the FDA’s go-ahead for home injections and now will take that into the future with plans to discuss extending use beyond the pandemic, Harris said.

Crysvita sales for 2020 are expected to hit between $135 million and $137 million. Company revenue estimates for 2021 fall in the $180 million to $190 million range. Piper Sandler analysts pointed out in an investor note that Ultragenyx revenue guidance is in line with its expectations, adding that its “pipeline progress continues on track, and we continue to like the setup on this name.”

Ultragenyx’s two 2020 approvals represent the third and fourth since Ultragenyx began in 2010. Up next? A pipeline and a plan to reach $1 billion in sales in the next five years.

“The momentum generated by those new approvals, along with the clinical pipeline, form our foundation for the next five years,” Harris said.



Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...